1. Scrip
  2. >>Business
  3. >>Strategy

NeuroDerm Makes Progress On Simplified Path To Parkinson's Approval

 
• By Mandy Jackson

NeuroDerm Ltd. reported Phase II results for its drug-device combination product ND0612 that reinforce its ability to fill a gap in the treatment of advanced Parkinson's disease, and it could be on the market in the US in less than three years if the company is able to stay on its revised development path.

Human brain illustrated with millions of small nerves - Conceptual 3d render

ND0612 uses an external pump to provide continuous delivery of carbidopa and levodopa in an attempt to prevent "off" periods that patients experience when oral versions of the drugs stop working before it is time to take another dose. Rehovot, Israel-based NeuroDerm is positioning the product candidate as a first-line treatment for advanced Parkinson's patients who otherwise would transition from oral therapy to AbbVie Inc.'s Duopa (carbidopa/levodopa enteral suspension) or deep brain stimulation – treatments that both require surgical procedures.

Scrip spoke with NeuroDerm CEO Oded Lieberman in January during the J.P. Morgan Healthcare Conference about the value that ND0612...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

BIO Notebook: Woodcock Calls For Doing The Right Thing, Dealmaking Remains Constrained

 
• By Mandy Jackson, Joseph Haas, and Sarah Karlin-Smith

Highlights from Day Four of the BIO International Convention include Woodcock offering practical advice on rare disease trials, the sorry state of dealmaking mid-year, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.

ASCO: Pushing The Frontiers Of ADCs

 
• By Mary Jo Laffler

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.

Skyhawk Looks To Soar With Huntington’s Hope

 
• By Kevin Grogan

Oral RNA splicing modulator has gone into a Phase II/III trial

BIO Notebook: MFN Pricing, Next-Gen Obesity R&D, FDA’s Rare Disease Hub & Reaction To Review Program

 
• By Sarah Karlin-Smith, Mandy Jackson, and Alaric DeArment

Highlights from Day 3 of the BIO International Convention include the realities of MFN pricing, AstraZeneca's R&D plans for obesity, the need for resources for FDA's rare disease hub and reactions to the Commissioner's National Priority Review Voucher program.

More from Business

Top 10 Drugs Q1 2025: Keytruda Dominates; Mounjaro Climbs

 
• By Eleanor Malone

Lilly’s Mounjaro for diabetes rose from sixth to third position among the top-selling drugs in the first quarter of 2025, Rival Ozempic retained second position and Merck & Co’s immuno-oncology blockbuster Keytruda stayed far ahead.

Skyhawk Looks To Soar With Huntington’s Hope

 
• By Kevin Grogan

Oral RNA splicing modulator has gone into a Phase II/III trial

BIO Notebook: MFN Pricing, Next-Gen Obesity R&D, FDA’s Rare Disease Hub & Reaction To Review Program

 
• By Sarah Karlin-Smith, Mandy Jackson, and Alaric DeArment

Highlights from Day 3 of the BIO International Convention include the realities of MFN pricing, AstraZeneca's R&D plans for obesity, the need for resources for FDA's rare disease hub and reactions to the Commissioner's National Priority Review Voucher program.